P-cell dysfunction in type 2 diabetes mellitus: the possibilities of modern antihyperglycemic therapy
- 作者: Chernikova N.A.1
-
隶属关系:
- Russian Medical Academy of Continuous Professional Education
- 期: 卷 28, 编号 12 (2021)
- 页面: 60-65
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313296
- DOI: https://doi.org/10.18565/pharmateca.2021.12.60-65
- ID: 313296
如何引用文章
详细
This review reveals the current understanding of the role of в-cell dysfunction in the onset and development of type 2 diabetes mellitus (T2DM). The pathological processes underlying the impaired insulin secretion in T2DM are described. The data on the influence of modern antihyperglycemic therapy on the functional state of в-cells are presented.
全文:
作者简介
Natalia Chernikova
Russian Medical Academy of Continuous Professional EducationCand. Sci. (Med.), Associate Professor at the Department of Endocrinology
参考
- Ludvik B., Nolan J.J., Baloga J., Sacks D., Olefsky J. Effect of obesity on insulin resistance in normal subjects and patients with NIDDM. Diabetes. 1995;44:1121-25. Doi: 10.2337/ diab.44.9.1121.
- Polonsky K.S. Dynamics of insulin secretion in obesity and diabetes. Int J Obes Relat Metab Disord. 2000;24(Suppl. 2):S29-S31. Doi: 10.1038/ sj.ijo.0801273.
- Ferrannini E., Natali A., Bell P, et al. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest. 1997;100(5):1166- 73. doi: 10.1172/JCI119628.
- Tabak A.G., Jokela M., Akbaraly T.N., et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373:2215-21. Doi: 10.1016/ S0140-6736(09)60619-X.
- Weir G.C., Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 2004;53(Suppl 3):S16-21. doi: 10.2337/diabetes.53.suppl_3.s16.
- Brown R.J., Rother K.I. Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data. Pediatr Diabetes. 2008;9(3 Pt 2):14-22. doi: 10.1111/j.1399-5448.2007.00272.
- Ferrannini E. The stunned beta cell: a brief history. Cell Metab. 2010;11(5):349-52. Doi: 10.1016/j. cmet.2010.04.009.
- Butler A.E., Janso J., Bonner-Weir S., et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102-10. doi: 10.2337/diabetes.52.1.102.
- Rahier J., Guiot Y., Goebbels R.M., et al. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab. 2008;10(Suppl. 34-42-42. doi: 10.1111/j.1463- 1326.2008.00969.x.
- Halban P.A., Polonsky K.S., Bowden D.W., et al. в -cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. J Clin Endocrinol Metab. 2014;99(6):1983-92. doi: 10.1210/jc.2014-1425.
- Eizirik D.L., Cardozo A.K., Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocrinol Rev. 2008;29:42-61. Doi: 10.1210/ er.2007-0015
- Laybutt D.R., Preston A.M., Akerfeldt M.C., et al. Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes. Diabetologia. 4007;50:754-63. doi: 10.1007/300125-006-0590-z
- Tiedge M., LortzS., Drinkgern J., LenzenS. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes. 1997;46:1733-42. Doi: 10.2337/ diab.46.11.1733.
- Kruit J.K., Wijesekara N., Fox J.E., et al. Islet cholesterol accumulation due to loss of ABCA1 leads to impaired exocytosis of insulin granules. Diabetes. 2011;60:3186-96. Doi: 10.2337/ db11-0081.
- Del Guerra S, Lupi R, Marselli L, et al. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes. 2005;54:727-35. doi: 10.2337/diabetes.54.3.727.
- Masters S.L., Dunne A., Subramanian S.L., et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1b in type 2 diabetes. Nat Immunol. 2010;11:897-904. doi: 10.1038/ni.1935.
- Richardson S.J., Willcox A., Bone A.J., Foulis A.K., Morgan N.G. Islet-associated macrophages in type 2 diabetes. Diabetologia. 2009;52:1686-88. doi: 10.1007/s00125-009-1410-z
- Boni-Schnetzler M., Thorne J., Parnaud G., et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab. 2008;93:4065-74. doi: 10.1210/jc.2008-0396.
- Larsen C.M., Faulenbach M., Vaag A., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1517-26. doi: 10.1056/NEJMoa065213.
- Robertson R.P, Harmon J., Tran PO., Tanaka Y., Takahashi H. Glucose toxicity in в-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes. 2003;52:581. doi: 10.2337/diabetes.52.3.581.
- Tabk A.G, Jokela M., Akbaraly T.N., et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373(9682):2215-21. doi: 10.1016/S0140-6736(09)60619-X.
- Russo G.T, Giorda C.B., Cercone S., et al. Beta cell stress in a 4-year follow-up of patients with type 2 diabetes: a longitudinal analysis of the BetaDecline Study. Diabetes Metab Res Rev. 2018;34(6):e3016. doi: 10.1002/dmrr.3016.
- Hou X., Liu J., Song J., et al. Relationship of Hemoglobin A1c with в Cell Function and Insulin Resistance in Newly Diagnosed and Drug Naive Type 2 Diabetes Patients. J Diabetes Res. 2016;2016:8797316. doi: 10.1155/2016/87973 1 6.
- Gleason C.E., Gonzalez M., Harmon J.S., Robertson R.P Determinants of glucose toxicity and its reversibility in the pancreatic islet betacell line, HIT-T15. Am J Physiol Endocrinol Metab. 2000;279:E997-1002. Doi: 10.1152/ ajpendo.2000.279.5.E997.
- Poitout V., Amyot J., Semache M., et al. Glucolipotoxicity of the pancreatic beta cell. Biochim Biophys Acta. 2010;1801:289-98. doi: 10.1016/j.bbalip.2009.08.006.
- Cunha D.A., Hekerman., Cardozo A.K., Bellomo, E., et al. Initiation and execution of lipotoxic ER stress in pancreatic beta-cells. J Cell Sci. 2008;121:2308- 18. doi: 10.1242/jcs.026062.
- Weng J., Li Y, Xu W., et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomized parallel-group trial. Lancet 2008;371:1753-60. Doi: 10.1016/ S0140-6736(08)60762-X.
- Ashcroft F.M., Gribble F.M. ATP-sensitivi K+channels and insulin secretion: their role in health and disease. Diabetologia. 1999;2(8):903- doi: 10.1007/s001250051247.
- Bunck M.C., Diamant M., Corner A., et al. One-year treatment with exenatide improves betacell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009;32:762-68. doi: 10.2337/dc08-1797.
- Gerstein H.C, Bosch J., Dagenais G.R., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319-28. doi: 10.1056/NEJMoa1203858.
- Mcinnes N., Hall S., et al. 677-P: Remission of Type 2 Diabetes following Intensive Treatment with Insulin Glargine, Lixisenatide, Metformin, and Lifestyle Approaches: Results of a Multicenter Randomized Controlled Trial. Diabetes. 2021;70(Supplement 1):677-P Doi:10.2337/ db21-677-P.
- Xu W., Li Y.B., Deng W.P, Hao Y.T., Weng J.P Remission of hyperglycemia following intensive insulin therapy in newly diagnosed type 2 diabetic patients: a long-term follow-up study. Chinese Med Jio2009;122:2554-59.
- Retnakaran R., Zinman B. Short-term intensified insulin treatment in type 2 diabetes: longterm effects on beta-cell function. Diabetes Obes Metab 00J0;J4(Suppl doi: 10.1111/j.1463-1326.2012.01658.x.
- Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-43. doi: 10.1056/NEJMoa066224.
- Patane G., Piro S., Rabuazzo A.M., et al. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes 2000;49:735-40. Doi: 0.2337/ diabetes.49.5.735.
- Simon-Szabo L., Kokas M., Mandl J., et al. Metformin attenuates palmitate induced endoplasmic reticulum stress, serine phosphorylation of IRS-1 and apoptosis in rat insulinoma cells. PLoS One. 2014;9:e97868. doi: 10.1371/journal.pone.0097868.
- DeFronzo R.A., Tripathy D., Schwenke D.C., et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104-doi: 10.1056/NEJMoa1010949.
- Lupi R., Del Guerra S., Marselli L., et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab. 6004;286:E560-61.Doi: 10.1152/ ajpendo.00561.2002.
- Russo G.T., Giorda C.B., Cercone S., et al. Factors associated with beta-cell dysfunction in type 2 diabetes: the BETADECLINE study. PLoS One. 2014;9(10):e109702. doi: 10.1371/jEurnal. pEne.0109702.
- Maedler K., Carr R.D., Bosco D., et al. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab. 0--5;9-:5-1-4. doi: 10.1210/jc.2004-0699.
- UK Prospective Diabetes Study 16: Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58. doi: 10.2337/diab.44.11.1249.
- Kahn S.E., Lachin J.M., Zinman B., et al. Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. Diabetes. 0-JJ;4-:J550-4-. Doi: 10.2337/ db10-1392.
- Drucker D.J., Philippe J., S., et al. Glucagon like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. ProcNatl Acad Sci USA. 1987;84:3434-38. doi: 10.1073/pnas.84.10.3434.
- Xu G., Stoffers D.A., Habener J.F., Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270-76. Doi: 10.2337/ diabetes.48.12.2270.
- Farilla L., Bulotta A., Hirshberg B., et al. Glucagonlike peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144:5149-58. doi: 10.1210/en.2003-0323.
- Derosa G., Carbone A., DAngelo A., et al. A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and beta-cell function. Expert Opin PhormocECher. 2-12;13:2433-42. doi: 10.1517/14656566.2012.730519.
- Ohkura T., Fujioka Y., Sumi K., et al. Sitogliptin improves the impaired acute insulin response during a meal tolerance test in Japanese patients with type 2 diabetes mellitus: a small-scale real-world study. Diabetes Ther. 2014;5:285-97. doi: 10.1007/s13300-014-0071-1.
- Cunha D.A, Ladriere L, Ortis F., et al. Glucagon like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes. 2009;58:2851-62. doi: 1-.2337/db-9--485.
- NotolicchiE A., Labarbuta R., TErtEso F, et al. Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and the MKK4/7 stress kinase signalling pathway. 6iobetEbgio. 2-J3;56:2456-66. doi: 10.1007/s00125-013-3028-4.
- Shimo N., Matatoua T.A., Miyotsuko T., et al. Short-term selective alleviation of glucotoxicity and lipotoxicity ameliorates the suppressed expression of key beta-cell factors under diabetic conditions. Biochem Biophys Res Commun. 2015;467:948-doi: 10.1016/j.bbrc.2015.10.038.
- Okauchi S., Shimoda M., A., et al. Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic beta-cells in obese type 0 diabetic db/db mice. Biochem Biophys Res Commun. 2-J4;47-:772-82. Doi: 10.1016/j. bbrc.2015.10.109.
- Rosenstock J., Aggarwal N., D., et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 0-J0;35:J030-38. Doi: 10.0337/ dc11-1926.
- Matthews D.R., Paldanius PM., P, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 0 diabetes (VERIFY): A 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394:1519-29. Doi: 10.1016/ S0140-6736(19)32131-2.
- Meier J.J., Schenker N., Kahle M., et al. Impact of insulin glargine and lixisenotide on в-cell function in patients with type 2 diabetes mellitus: A randomized open-label study. Diabetes Obes Metab. 2017;19(11):1625-29. Doi: 10.1111/ dom.10968.